Skip to main content
Top
Published in: Osteoporosis International 4/2019

01-04-2019 | Osteoporosis | Original Article

Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study

Authors: W.-J. Chen, H. Livneh, M.-H. Hsieh, C.-C. Yeh, M.-H. Yeh, M.-C. Lu, J.-T. Chien, T.-Y. Tsai

Published in: Osteoporosis International | Issue 4/2019

Login to get access

Abstract

Summary

After utilizing a large population-based claims database and the application of propensity score match approach to reduce the confounding effects, we found that the use of Chinese herbal medicines (CHMs) was related to the lower risk of sequent osteoporotic fracture by 27% among the individuals with osteoporosis. The predominant effect was observed in those receiving CHMs for more than two years.

Introduction

Osteoporosis (OS) is a highly disabling condition that can lead to fragility fracture, thus posing greater burdens of functional limitations for the affected individuals. It is unclear if the use of Chinese herbal medicines (CHMs) could reduce the risk of fracture due to OS. This study aimed to investigate the association of CHMs and the subsequent osteoporotic fracture risk among OS patients.

Methods

This longitudinal cohort study used the Taiwanese National Health Insurance Research Database to identify 250,699 newly diagnosed OS patients aged 20 years or older between 1998 and 2010. We recruited 103,325 CHM users following the onset of OS (CHM users) and randomly selected 103,325 subjects without CHM usage as controls (non-CHM users) by propensity score matching according to the demographic characteristics and comorbidities at enrollment. All enrollees were followed until the end of 2012 to record the incidence of osteoporotic fracture. We applied the Cox proportional hazard regression model to compute the hazard ratio (HR) of the risk of osteoporotic fracture.

Results

During the 15-year follow-up period, 7208 CHM users and 11,453 non-CHM users sustained osteoporotic fracture, with an incidence rate of 9.26 and 12.96, respectively, per 1000 person-years. We found that CHM users had a significantly reduced risk of osteoporotic fracture compared to non-CHM users (adjusted HR 0.73; 95% confidence interval [CI] = 0.70–0.75). Those treated with CHMs for longer than 730 days had a lower fracture risk by 54%. Some commonly used CHMs, such as Yan hu suo (Rhizoma Corydalis), Huang Qin (Scutellaria Baicale), Jie Geng (Platycodon grandifloras), Xiang Fu (Cyperus rotundus), Hai Piao Xiao (Cuttlebone Sepium), Jia-Wei-Xiao-Yao-San, Ge-Gen-Tang, Shao-Yao-Gan-Cao-Tang, and Du-Huo-Ji-Sheng-Tang, are related to the lower risk of fracture.

Conclusions

The use of CHMs was associated with lower risk of osteoporotic fracture for OS patients, suggesting that it could be integrated into conventional therapy to prevent subsequent bone fracture.
Literature
1.
go back to reference Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jöhnsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef Hernlund E, Svedbom A, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jöhnsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef
2.
go back to reference Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess 28:1–2 Nelson HD, Morris CD, Kraemer DF, Mahon S, Carney N, Nygren PM, Helfand M (2001) Osteoporosis in postmenopausal women: diagnosis and monitoring. Evid Rep Technol Assess 28:1–2
4.
go back to reference Klop C, Welsing PM, Cooper C, Harvey NC, Elders PJ, Bijlsma JW, Leufkens HG, de Vries F (2014) Mortality in British hip fracture patients, 2000–2010: a population-based retrospective cohort study. Bone 66:171–177CrossRef Klop C, Welsing PM, Cooper C, Harvey NC, Elders PJ, Bijlsma JW, Leufkens HG, de Vries F (2014) Mortality in British hip fracture patients, 2000–2010: a population-based retrospective cohort study. Bone 66:171–177CrossRef
5.
go back to reference Schuiling KD, Robinia K, Nye R (2011) Osteoporosis update. J Midwifery Womens Health 56(6):615–627CrossRef Schuiling KD, Robinia K, Nye R (2011) Osteoporosis update. J Midwifery Womens Health 56(6):615–627CrossRef
6.
go back to reference Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475CrossRef Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A (2007) Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 22(3):465–475CrossRef
7.
go back to reference Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84(7):632–637CrossRef Kennel KA, Drake MT (2009) Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 84(7):632–637CrossRef
8.
go back to reference McGreevy C, Williams D (2011) Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2(4):159–172CrossRef McGreevy C, Williams D (2011) Safety of drugs used in the treatment of osteoporosis. Ther Adv Drug Saf 2(4):159–172CrossRef
9.
go back to reference So RWL, Wong HS, Ko KM (2015) A traditional Chinese medicine approach in treating depression by promoting liver qi circulation: a Western medicine perspective. Chin Med 6:187–195CrossRef So RWL, Wong HS, Ko KM (2015) A traditional Chinese medicine approach in treating depression by promoting liver qi circulation: a Western medicine perspective. Chin Med 6:187–195CrossRef
10.
go back to reference Chen KH, Yeh MH, Livneh H, Chen BC, Lin IH, Lu MC, Tsai TY, Yeh CC (2017) Association of traditional Chinese medicine therapy and the risk of dementia in patients with hypertension: a nationwide population-based cohort study. BMC Complement Altern Med 17:178CrossRef Chen KH, Yeh MH, Livneh H, Chen BC, Lin IH, Lu MC, Tsai TY, Yeh CC (2017) Association of traditional Chinese medicine therapy and the risk of dementia in patients with hypertension: a nationwide population-based cohort study. BMC Complement Altern Med 17:178CrossRef
11.
go back to reference Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC (2017) Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open 7(1):e014571CrossRef Tsai TY, Livneh H, Hung TH, Lin IH, Lu MC, Yeh CC (2017) Associations between prescribed Chinese herbal medicine and risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide population-based cohort study. BMJ Open 7(1):e014571CrossRef
12.
go back to reference Tsai TY, Li CY, Livneh H, Lin IH, Lu MC, Yeh CC (2016) Decreased risk of stroke in patients receiving traditional Chinese medicine for vertigo: a population-based cohort study. J Ethnopharmacol 184:138–143CrossRef Tsai TY, Li CY, Livneh H, Lin IH, Lu MC, Yeh CC (2016) Decreased risk of stroke in patients receiving traditional Chinese medicine for vertigo: a population-based cohort study. J Ethnopharmacol 184:138–143CrossRef
13.
go back to reference Chung VC, Wu X, Lu P, Hui EP, Zhang Y, Zhang AL, Ay L, Zhao J, Fan M, Ziea ET, Ng BF, Wong SY, Wu JC (2016) Chinese herbal medicine for symptom management in cancer palliative care: systematic review and meta-analysis. Medicine (Baltimore) 95(7):e2793CrossRef Chung VC, Wu X, Lu P, Hui EP, Zhang Y, Zhang AL, Ay L, Zhao J, Fan M, Ziea ET, Ng BF, Wong SY, Wu JC (2016) Chinese herbal medicine for symptom management in cancer palliative care: systematic review and meta-analysis. Medicine (Baltimore) 95(7):e2793CrossRef
14.
go back to reference Ren YB, Huang JH, Cai WJ, Shen ZY (2015) Shen-Jing as a Chinese medicine concept might be a counterpart of stem cells in regenerative medicine. Chin J Integr Med Epub ahead print Ren YB, Huang JH, Cai WJ, Shen ZY (2015) Shen-Jing as a Chinese medicine concept might be a counterpart of stem cells in regenerative medicine. Chin J Integr Med Epub ahead print
15.
go back to reference Shu B, Shi Q, Wang YJ (2015) Shen (kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome. Chin J Integr Med 21:656–661CrossRef Shu B, Shi Q, Wang YJ (2015) Shen (kidney)-tonifying principle for primary osteoporosis: to treat both the disease and the Chinese medicine syndrome. Chin J Integr Med 21:656–661CrossRef
16.
go back to reference Choi JH, Han Y, Kim YA, Jin SW, Lee GH, Jeong HM, Lee HS, Chung YC, Lee YC, Kim EJ, Lee KY, Jeong HG (2017) Platycodin D inhibits osteoclastogenesis by repressing the NFATc1 and MAPK signaling pathway. J Cell Biochem 118(4):860–868CrossRef Choi JH, Han Y, Kim YA, Jin SW, Lee GH, Jeong HM, Lee HS, Chung YC, Lee YC, Kim EJ, Lee KY, Jeong HG (2017) Platycodin D inhibits osteoclastogenesis by repressing the NFATc1 and MAPK signaling pathway. J Cell Biochem 118(4):860–868CrossRef
17.
go back to reference Liu Y, Liu JP, Xia Y (2014) Chinese herbal medicines for treating osteoporosis. Cochrane Database Syst Rev 3:CD005467 Liu Y, Liu JP, Xia Y (2014) Chinese herbal medicines for treating osteoporosis. Cochrane Database Syst Rev 3:CD005467
19.
go back to reference Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M (2003) Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 85-A(12):2294–2302CrossRef Feldstein AC, Nichols GA, Elmer PJ, Smith DH, Aickin M, Herson M (2003) Older women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg Am 85-A(12):2294–2302CrossRef
20.
go back to reference Lin TK, Liou YS, Lin CH, Chou P, Jong GP (2018) High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol 10:159–165CrossRef Lin TK, Liou YS, Lin CH, Chou P, Jong GP (2018) High-potency statins but not all statins decrease the risk of new-onset osteoporotic fractures: a nationwide population-based longitudinal cohort study. Clin Epidemiol 10:159–165CrossRef
21.
go back to reference Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY (2006) Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 4(1):1–22 Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, Liang KY (2006) Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag 4(1):1–22
22.
go back to reference Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRef Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45(6):613–619CrossRef
23.
go back to reference Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, Shi Q, Cui XJ, Wang YJ (2013) Chinese herbal medicine for osteoporosis: a systematic review of randomized controlled trails. Evid Based Complement Alternat Med 2013:356260PubMedPubMedCentral Wang ZQ, Li JL, Sun YL, Yao M, Gao J, Yang Z, Shi Q, Cui XJ, Wang YJ (2013) Chinese herbal medicine for osteoporosis: a systematic review of randomized controlled trails. Evid Based Complement Alternat Med 2013:356260PubMedPubMedCentral
24.
go back to reference Che CT, Wong MS, Lam CW (2016) Natural products from Chinese medicines with potential benefits to bone health. Molecules 21(3):239CrossRef Che CT, Wong MS, Lam CW (2016) Natural products from Chinese medicines with potential benefits to bone health. Molecules 21(3):239CrossRef
25.
go back to reference Shih CC, Liao CC, Su YC, Tsai CC, Lin JG (2012) Gender differences in traditional Chinese medicine use among adults in Taiwan. PLoS One 7(4):e32540CrossRef Shih CC, Liao CC, Su YC, Tsai CC, Lin JG (2012) Gender differences in traditional Chinese medicine use among adults in Taiwan. PLoS One 7(4):e32540CrossRef
26.
go back to reference Wang JY, Chen WM, Wen CS, Hung SC, Chen PW, Chiu JH (2017) Du-Huo-Ji-Sheng-Tang and its active component Ligusticum chuanxiong promote osteogenic differentiation and decrease the aging process of human mesenchymal stem cells. J Ethnopharmacol 198:64–72CrossRef Wang JY, Chen WM, Wen CS, Hung SC, Chen PW, Chiu JH (2017) Du-Huo-Ji-Sheng-Tang and its active component Ligusticum chuanxiong promote osteogenic differentiation and decrease the aging process of human mesenchymal stem cells. J Ethnopharmacol 198:64–72CrossRef
27.
go back to reference Lee SC, Wu SH, Hsiao TH, Yang YC, Tien YC (2005) Effects of Chia-wei-hsiao-yao-san on bone loss in ovariectomized rats. J Food Drug Anal 13(3):232–238 Lee SC, Wu SH, Hsiao TH, Yang YC, Tien YC (2005) Effects of Chia-wei-hsiao-yao-san on bone loss in ovariectomized rats. J Food Drug Anal 13(3):232–238
29.
go back to reference Yuan SY, Sheng T, Liu LQ, Zhang YL, Liu XM, Ma T, Zheng H, Yan Y, Ishimi Y, Wang XX (2016) Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro. Chin J Nat Med 14(4):265–269PubMed Yuan SY, Sheng T, Liu LQ, Zhang YL, Liu XM, Ma T, Zheng H, Yan Y, Ishimi Y, Wang XX (2016) Puerarin prevents bone loss in ovariectomized mice and inhibits osteoclast formation in vitro. Chin J Nat Med 14(4):265–269PubMed
30.
go back to reference Ok HM, Gebreamanuel MR, Oh SA, Jeon H, Lee WJ, Kwon O (2015) A root-based combination supplement containing Pueraria lobata and Rehmannia glutinosa and exercise preserve bone mass in ovariectomized rats fed a high-fat diet. Calcif Tissue Int 97(6):624–633CrossRef Ok HM, Gebreamanuel MR, Oh SA, Jeon H, Lee WJ, Kwon O (2015) A root-based combination supplement containing Pueraria lobata and Rehmannia glutinosa and exercise preserve bone mass in ovariectomized rats fed a high-fat diet. Calcif Tissue Int 97(6):624–633CrossRef
31.
go back to reference Ji M, Liu Y, Yang S, Zhai D, Zhang D, Bai L, Wang Z, Yu J, Yu C, Cai Z (2013) Puerarin suppresses proliferation of endometriotic stromal cells in part via differential recruitment of nuclear receptor coregulators to estrogen receptor-α. J Steroid Biochem Mol Biol 138:421–426CrossRef Ji M, Liu Y, Yang S, Zhai D, Zhang D, Bai L, Wang Z, Yu J, Yu C, Cai Z (2013) Puerarin suppresses proliferation of endometriotic stromal cells in part via differential recruitment of nuclear receptor coregulators to estrogen receptor-α. J Steroid Biochem Mol Biol 138:421–426CrossRef
32.
go back to reference Chen G, Jia P, Gao X (2012) Effect and mechanism of shao-yao gan-cao tang on adjuvant-induced arthritis in rats. Afr J Pharm Pharmacol 6(22):1611–1616 Chen G, Jia P, Gao X (2012) Effect and mechanism of shao-yao gan-cao tang on adjuvant-induced arthritis in rats. Afr J Pharm Pharmacol 6(22):1611–1616
33.
go back to reference Barksby HE, Lea SR, Preshaw PM, Taylor JJ (2007) The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149(2):217–225CrossRef Barksby HE, Lea SR, Preshaw PM, Taylor JJ (2007) The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149(2):217–225CrossRef
34.
go back to reference Mukudai Y, Kondo S, Koyama T, Li C, Banka S, Kogure A, Yazawa K, Shintani S (2014) Potential anti-osteoporotic effects of herbal extracts on osteoclasts, osteoblasts and chondrocytes in vitro. BMC Complement Altern Med 14:29CrossRef Mukudai Y, Kondo S, Koyama T, Li C, Banka S, Kogure A, Yazawa K, Shintani S (2014) Potential anti-osteoporotic effects of herbal extracts on osteoclasts, osteoblasts and chondrocytes in vitro. BMC Complement Altern Med 14:29CrossRef
35.
go back to reference Kum CJ, Kim EY, Kim JH, Lee B, Min JH, Heo J, Kim JH, Yeom M, Sohn Y, Jung HS (2017) Cyperus rotundus L extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat. J Ethnopharmacol 205:186–194CrossRef Kum CJ, Kim EY, Kim JH, Lee B, Min JH, Heo J, Kim JH, Yeom M, Sohn Y, Jung HS (2017) Cyperus rotundus L extract suppresses RANKL-induced osteoclastogenesis through NFATc1/c-fos downregulation and prevent bone loss in OVX-induced osteoporosis rat. J Ethnopharmacol 205:186–194CrossRef
36.
go back to reference Guo AJ, Choi RC, Cheung AW, Chen VP, Xu SL, Dong TT, Chen JJ, Tsim KW (2011) Baicalin, a flavone, induces the differentiation of cultured osteoblasts: an action via the Wnt/beta-catenin signaling pathway. J Biol Chem 286(32):27882–27893CrossRef Guo AJ, Choi RC, Cheung AW, Chen VP, Xu SL, Dong TT, Chen JJ, Tsim KW (2011) Baicalin, a flavone, induces the differentiation of cultured osteoblasts: an action via the Wnt/beta-catenin signaling pathway. J Biol Chem 286(32):27882–27893CrossRef
37.
go back to reference Liu Y, Uy J, Bai J, Gu JS, Cai B, Zhou X (2013) Effects of cuttlefish bone–bone morphogenetic protein composite material on osteogenesis and revascularization of bone defect in rats. Zhonghua Shao Shang Za Zhi 29(6):548–553PubMed Liu Y, Uy J, Bai J, Gu JS, Cai B, Zhou X (2013) Effects of cuttlefish bone–bone morphogenetic protein composite material on osteogenesis and revascularization of bone defect in rats. Zhonghua Shao Shang Za Zhi 29(6):548–553PubMed
38.
go back to reference Cozza N, Monte F, Bonani W, Aswath P, Motta A, Migliaresi C (2018) Bioactivity and mineralization of natural hydroxyapatite from cuttlefish bone and bioglass co-sintered bioceramics. J Tissue Eng Regen Med 12(2):e113–e1142CrossRef Cozza N, Monte F, Bonani W, Aswath P, Motta A, Migliaresi C (2018) Bioactivity and mineralization of natural hydroxyapatite from cuttlefish bone and bioglass co-sintered bioceramics. J Tissue Eng Regen Med 12(2):e113–e1142CrossRef
39.
go back to reference Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102(3):179–186CrossRef Lai MN, Wang SM, Chen PC, Chen YY, Wang JD (2010) Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102(3):179–186CrossRef
Metadata
Title
Association of use of Chinese herbal medicines and the risk of fracture in patients with osteoporosis: a population-based cohort study
Authors
W.-J. Chen
H. Livneh
M.-H. Hsieh
C.-C. Yeh
M.-H. Yeh
M.-C. Lu
J.-T. Chien
T.-Y. Tsai
Publication date
01-04-2019
Publisher
Springer London
Published in
Osteoporosis International / Issue 4/2019
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-018-4789-x

Other articles of this Issue 4/2019

Osteoporosis International 4/2019 Go to the issue